Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “AstraZeneca”

A Study to Investigate the Safety, Tolerability and Pharmacodynamics of AZD4144 in Participants With ObesityCompleted
NCT06942923Phase 1Updated Oct 7, 2025
Sponsor: AstraZeneca
Healthy Participants
Germany
Radiation Therapy in Combination With Durvalumab for People With Pancreatic CancerActive Not Recruiting
NCT03245541Phase 1, Phase 2Updated Oct 7, 2025
Sponsor: Memorial Sloan Kettering Cancer Center
Pancreatic Adenocarcinoma
United States
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]Active Not Recruiting
NCT03734029Phase 3Updated Oct 6, 2025
Sponsor: Daiichi Sankyo
Breast Cancer
United States, Austria, Belgium, Canada, China +15 more
A Safety, Pharmacokinetic, and Pharmacodynamic Study of Once Daily Inhaled AZD8630 in Adults With AsthmaCompleted
NCT06795906Phase 1Updated Oct 3, 2025
Sponsor: AstraZeneca
Asthma
Germany
Study of Relationship Between Changes in Inflammation, Lung Function, Symptoms and Medication Use in COPD PatientsCompleted
NCT04168216N/AUpdated Oct 2, 2025
Sponsor: AstraZeneca
Pulmonary Disease, Chronic Obstructive
United Kingdom
Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin LymphomaCompleted
NCT05216835Phase 1Updated Oct 2, 2025
Sponsor: AstraZeneca
Relapsed or Refractory Classical Hodgkin Lymphoma
United States, Canada, Denmark, France, Italy +2 more
Observational Retrospective Study To Characterize and Assess Clinical Outcomes of Patients Receiving Tezepelumab in the Framework Of Use in Special Situations Prior to Commercialisation in SpainCompleted
NCT06487065N/AUpdated Oct 2, 2025
Sponsor: AstraZeneca
Severe Asthma
Spain
Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast CancerActive Not Recruiting
NCT02826434Phase 1Updated Oct 1, 2025
Sponsor: Massachusetts General Hospital
Breast Cancer
United States
Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic CancerCompleted
NCT04257448Phase 1, Phase 2Updated Sep 30, 2025
Sponsor: GWT-TUD GmbH
Pancreas Cancer · Pancreatic Adenocarcinoma · Pancreatic Ductal Adenocarcinoma
Germany
Brazilian Reality of Hepatocellular CarcinomaCompleted
NCT06230328N/AUpdated Sep 29, 2025
Sponsor: AstraZeneca
Hepatocellular Carcinoma · Hepatocellular Carcinoma by BCLC Stage · Hepatocellular Carcinoma Stage I · Hepatocellular Carcinoma Stage II
Brazil
Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate CancerCompleted
NCT03516812Phase 2Updated Sep 29, 2025
Sponsor: University of Washington
Castration-Resistant Prostate Carcinoma · Prostate Adenocarcinoma
United States
PROPE Severe Asthma Study in EgyptCompleted
NCT06283290N/AUpdated Sep 26, 2025
Sponsor: AstraZeneca
Severe Asthma
Egypt
Guideline Directed Medical Therapy in Patients With Heart FailureCompleted
NCT06700213N/AUpdated Sep 25, 2025
Sponsor: Massachusetts General Hospital
Heart Failure
United States
AZD3427 Effects on Renal Perfusion in Heart Failure Patients With Reduced Ejection Fraction and Renal ImpairmentTerminated
NCT06611423Phase 1Updated Sep 24, 2025
Sponsor: AstraZeneca
Heart Failure With Reduced Ejection Fraction (HFrEF) · Renal Impairment
Sweden
A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD2389Completed
NCT06812780Phase 1Updated Sep 24, 2025
Sponsor: AstraZeneca
Hepatic Impairment
United States
Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE)Completed
NCT03373045N/AUpdated Sep 24, 2025
Sponsor: AstraZeneca
Asthma
United States, Puerto Rico
A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2Completed
NCT05737940Phase 2Updated Sep 24, 2025
Sponsor: AstraZeneca
Pulmonary Hypertension (World Health Organization Group 2) · Heart Failure
United States, Austria, Canada, China, Czechia +9 more
DOuBLED - Doubling Outcomes by Lung Cancer Early DiagnosisCompleted
NCT05091437N/AUpdated Sep 24, 2025
Sponsor: AstraZeneca
Pulmonary Nodules
Argentina, Brazil, Chile, Colombia, Costa Rica +3 more
A Phase Ib Study of AZD5462 on Top of Dapagliflozin in Participants With Heart Failure and Moderate Renal ImpairmentTerminated
NCT06639087Phase 1Updated Sep 24, 2025
Sponsor: AstraZeneca
Renal Impairment · Heart Failure
Bulgaria
Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid TumorsTerminated
NCT02938793Phase 2Updated Sep 23, 2025
Sponsor: Prisma Health-Upstate
Cancer · Rare Disease
United States
Olaparib Real-world Utilization and Clinical Outcomes in France, Italy, and the UKCompleted
NCT04532645N/AUpdated Sep 23, 2025
Sponsor: AstraZeneca
Ovary Cancer
France, Italy, United Kingdom
HER2 TREAT Study: Retrospective Study to Estimate the Prevalence of HER2-low in Unresectable and/or Metastatic Breast Cancer Patients Who Progress on Anti-Cancer Therapy Identified as HER2-Negative From Patient Medical Records in The Gulf Cooperation CouncilCompleted
NCT06125314N/AUpdated Sep 23, 2025
Sponsor: AstraZeneca
Breast Neoplasms · Breast Cancer · Breast Carcinoma · Genes
Kuwait, Qatar, Saudi Arabia, United Arab Emirates
Chlorhydrate of Ropivacaine and Breast Cancer SurgeryCompleted
NCT00370240Phase 4Updated Sep 22, 2025
Sponsor: Institut Curie
Breast Neoplasms · Pain,Postoperative
France
A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With a Next-Generation Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary DiseaseCompleted
NCT05573464Phase 3Updated Sep 19, 2025
Sponsor: AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
United States, Argentina, Bulgaria, Canada, Germany +4 more
TRUDI: TDXD+Durva in HER2+/Low IBCRecruiting
NCT05795101Phase 2Updated Sep 19, 2025
Sponsor: Filipa Lynce, MD
Invasive Breast Cancer · Inflammatory Breast Cancer Stage III · HER2-positive Breast Cancer · HER2 Low Breast Adenocarcinoma
United States

Previous page Next page